Drug Resistance, Neoplasm

"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.

Descriptor ID	D019008
MeSH Number(s)	G07.690.773.984.395
Concept/Terms	Drug Resistance, Neoplasm Drug Resistance, Neoplasm Resistance, Antineoplastic Agent Resistance, Antineoplastic Drug Drug Resistance, Antineoplastic Neoplasm Drug Resistance Antineoplastic Agent Resistance Antineoplastic Drug Resistance Antibiotic Resistance, Neoplasm Antibiotic Resistance, Neoplasm

Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".

Biological Sciences [G]
Physiological Phenomena [G07]
Pharmacological and Toxicological Phenomena [G07.690]
Pharmacological Phenomena [G07.690.773]
Drug Resistance [G07.690.773.984]
Drug Resistance, Neoplasm [G07.690.773.984.395]

Below are MeSH descriptors whose meaning is related to "Drug Resistance, Neoplasm".

Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in this website by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publications.

Bar chart showing 208 publications over 24 distinct years, with a maximum of 22 publications in 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	0	1	1
2003	1	2	3
2004	3	1	4
2005	1	4	5
2006	4	2	6
2007	4	3	7
2008	2	4	6
2009	4	2	6
2010	5	9	14
2011	4	5	9
2012	5	4	9
2013	7	8	15
2014	4	7	11
2015	7	5	12
2016	4	5	9
2017	6	3	9
2018	5	3	8
2019	7	15	22
2020	5	5	10
2021	10	2	12
2022	2	2	4
2023	1	5	6
2024	4	4	8
2025	4	8	12

Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.

Dela Cruz MC, Yao X, Nealy A, Bailey J, Nalls M, Medina PM, Chen R, Biliran H. BIT1 as an Effector of EGFR-TKI-induced Apoptosis via TLE1 Inhibition in Lung Adenocarcinoma Cells. Anticancer Res. 2026 Apr; 46(4):1799-1818.

View in: PubMed
Vuong NB, Korolkova OY, Izban MG, Sakwe NI, McIntosh AR, Ball DD, Black PJ, Edwards AD, Ballard BR, Adunyah SE, Sakwe AM. Contribution of Mesenchymal-like and Epithelial Cellular Subsets to Chemotherapy Resistance in Triple-Negative Breast Cancer. Int J Mol Sci. 2026 Mar 31; 27(7).

View in: PubMed
Chambers LM, Chalif J, Yao M, Reizes O, Rose PG, Michener CM, Vargas R. Gram-positive targeting antibiotics are associated with progression and death in women with platinum-sensitive recurrent high grade epithelial ovarian cancer. J Gynecol Oncol. 2026 01; 37(1):e69.

View in: PubMed
Chen Q, Dorji JP, Perera SG, Li P, Aijaz F, Ihuoma LC, Matsui H, Awah CU. In vivo inhibition of c-MYC in the metastatic drug-resistant ovarian cancer cells down regulates the c-MYC-PD-L1-PAX8-p21 to achieve therapeutic efficacy. BMC Cancer. 2025 Dec 10; 26(1):68.

View in: PubMed
Barajas J, Yang Z, Agyare E, Zhu X, Yoon SJ, Han B. Matrix stiffness influences drug resistance to gemcitabine analog and AZD 1775 combination in PDAC organoids. PLoS One. 2025; 20(12):e0326550.

View in: PubMed
Singh S, Weindorfer C, Nandi A, Panneer Selvam C, Mendes G?tze M, Das M, Falaschini A, Tjendra Y, Boone MM, Dolznig H, Zhang Q, Clarke R, Thomas C, Chakrabarti R. DLL1-responsive PD-L1+ tumor-associated macrophages promote endocrine resistance in breast cancer. Sci Transl Med. 2025 Nov 05; 17(823):eadr6207.

View in: PubMed
Zhao M, Ma Z, Parris AB, Yang X. LSR overexpression induces chemoresistance in triple negative breast cancer cells through MDR1 upregulation and apoptosis attenuation. PLoS One. 2025; 20(11):e0336124.

View in: PubMed
Singh A, Gupta I, Saha P, Hole A, Anthony F, Natu A, Smoot DT, Ashktorab H, Chilakapati MK, Gupta S. Raman spectroscopy for detecting gastric and liver cancer cells that entered a tolerant persistence state to survive cisplatin chemotherapy. Biochem Biophys Res Commun. 2025 11 19; 790:152891.

View in: PubMed
Ochoa PT, Sanchez-Hernandez ES, Duran AM, Cheng KW, Philip J, Suzuki T, Unternaehrer JJ, Dutil J, Das B, Ganguly R, Baca Y, de Semir D, Wang C, Kremsky I, Casiano CA. The GR-LEDGF/p75-HSP27 Axis Contributes to Cross-Resistance Between Enzalutamide and Docetaxel in Prostate Cancer. Cells. 2025 Oct 09; 14(19).

View in: PubMed
Singh A, Natu A, Anthony F, Muthu H, Khade B, Smoot DT, Ashktorab H, Gupta S. The synergistic action of HDAC inhibitor with cisplatin impedes survival and proliferation of drug-tolerant persister in gastric and liver cancer cells. Clin Epigenetics. 2025 Oct 08; 17(1):168.

View in: PubMed

People

Explore

Similar Concepts

Top Journals